MRK · Merck
424 filings
MRK SEC Filings
Merck - 424 total filings
MRK filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 88 current reports (8-K) between 2016 and 2026.
- 8-K · Feb 3, 2016
- 10-K · Feb 26, 2016
- 8-K · May 5, 2016
- 10-Q · May 9, 2016
- 8-K · May 27, 2016
- 8-K · Jul 29, 2016
- 10-Q · Aug 8, 2016
- 8-K · Oct 25, 2016
- 8-K · Nov 2, 2016
- 10-Q · Nov 7, 2016
- 8-K · Feb 2, 2017
- 8-K · Feb 23, 2017
- 10-K · Feb 28, 2017
- 8-K · May 2, 2017
- 10-Q · May 9, 2017
- 8-K · May 25, 2017
- 8-K · Jul 28, 2017
- 10-Q · Aug 8, 2017
- 8-K · Oct 27, 2017
- 8-K · Nov 6, 2017
- 10-Q · Nov 7, 2017
- 8-K · Jan 26, 2018
- 8-K · Feb 2, 2018
- 8-K · Feb 26, 2018
- 10-K · Feb 27, 2018
- 8-K · May 1, 2018
- 10-Q · May 8, 2018
- 8-K · May 24, 2018
- 8-K · Jul 27, 2018
- 10-Q · Aug 7, 2018
- 8-K · Sep 27, 2018
- 8-K · Oct 4, 2018
- 8-K · Oct 25, 2018
- 10-Q · Nov 6, 2018
- 8-K · Dec 10, 2018
- 8-K · Jan 30, 2019
- 8-K/A · Feb 1, 2019
- 8-K · Feb 1, 2019
- 10-K · Feb 27, 2019
- 8-K · Mar 7, 2019
- 8-K · Apr 30, 2019
- 10-Q · May 8, 2019
- 8-K · May 31, 2019
- 8-K · Jul 30, 2019
- 10-Q · Aug 6, 2019
- 8-K · Oct 29, 2019
- 10-Q · Nov 5, 2019
- 8-K · Jan 31, 2020
- 8-K · Feb 5, 2020
- 10-K · Feb 26, 2020
- 8-K · Apr 28, 2020
- 10-Q · May 6, 2020
- 8-K · May 29, 2020
- 8-K · Jun 24, 2020
- 8-K · Jul 31, 2020
- 10-Q · Aug 5, 2020
- 8-K · Oct 27, 2020
- 10-Q · Nov 5, 2020
- 8-K · Feb 1, 2021
- 8-K · Feb 4, 2021
- 8-K · Feb 4, 2021
- 10-K · Feb 25, 2021
- 8-K · Mar 24, 2021
- 8-K · Mar 26, 2021
- 8-K · Apr 29, 2021
- 8-K · May 5, 2021
- 10-Q · May 5, 2021
- 8-K · May 27, 2021
- 8-K · Jun 3, 2021
- 8-K · Jun 21, 2021
- 8-K · Jul 29, 2021
- 10-Q · Aug 9, 2021
- 8-K · Aug 20, 2021
- 8-K · Oct 28, 2021
- 10-Q · Nov 5, 2021
- 8-K · Dec 10, 2021
- 8-K · Feb 3, 2022
- 10-K · Feb 25, 2022
- 8-K · Mar 25, 2022
- 8-K · Apr 21, 2022
- 8-K · Apr 28, 2022
- 10-Q · May 5, 2022
- 8-K · May 26, 2022
- 8-K · Jul 28, 2022
- 10-Q · Aug 5, 2022
- 8-K · Oct 27, 2022
- 10-Q · Nov 3, 2022
- 8-K · Feb 2, 2023
- 10-K · Feb 24, 2023
- 8-K · Apr 27, 2023
- 10-Q · May 5, 2023
- 8-K · May 17, 2023
- 8-K · May 26, 2023
- 8-K · Aug 1, 2023
- 10-Q · Aug 7, 2023
- 8-K · Oct 26, 2023
- 10-Q · Nov 3, 2023
- 8-K · Nov 28, 2023
- 8-K · Feb 1, 2024
- 8-K · Feb 20, 2024
- 10-K · Feb 26, 2024
- 10-K/A · Apr 11, 2024
- 8-K · Apr 25, 2024
- 10-Q · May 3, 2024
- 8-K · May 30, 2024
- 8-K · Jul 30, 2024
- 10-Q · Aug 5, 2024
- 8-K · Oct 31, 2024
- 10-Q · Nov 6, 2024
- 8-K · Nov 22, 2024
- 8-K · Feb 4, 2025
- 10-K · Feb 25, 2025
- 8-K · Apr 24, 2025
- 10-Q · May 2, 2025
- 8-K · May 29, 2025
- 8-K · Jul 29, 2025
- 10-Q · Aug 5, 2025
- 8-K · Sep 9, 2025
- 8-K · Oct 30, 2025
- 10-Q · Nov 5, 2025
- 8-K · Dec 4, 2025
- 8-K · Feb 3, 2026
- 10-K · Feb 24, 2026
- 8-K · Apr 30, 2026
- 10-Q · May 4, 2026
- 8-K · May 22, 2026
- 8-K · May 28, 2026
- 8-K · Aug 4, 2026
- 10-Q · Aug 7, 2026
- 8-K · Oct 13, 2026
- 8-K · Oct 29, 2026
- 10-Q · Nov 4, 2026
- 8-K · Nov 18, 2026
Merck 8-K Report, Executive Changes (Nov 18, 2026)
This 8-K filing from Merck & Co., Inc. (MRK) primarily announces changes within its Board of Directors. Long-serving board member Thomas H. Glocer has notified the Company of his intention to retire from the Board at the 2027 Annual Meeting of Shareholders. This transition is not attributed to any disagreements with the Company's operations or policies. Concurrently, the independent members of the Board have appointed Douglas M. Baker, Jr. as the new independent lead director, effective January 1, 2027, succeeding Mr. Glocer in this capacity. Mr. Baker brings extensive experience in corporate governance, global marketing, sales, and operations from his previous role as CEO of Ecolab Inc. This leadership transition within the Board is a key focus of this report for investors.
Merck Quarterly Report for Q3 Ended Sep 30, 2026
Merck & Co., Inc. reported mixed financial results for the nine months ended September 30, 2026. While total sales increased by 5% year-over-year to $50.98 billion, driven by growth in oncology and animal health segments, the company incurred a significant net loss of $510 million attributable to Merck & Co., Inc. This loss is largely due to substantial research and development expenses associated with major acquisitions, including Cidara Therapeutics ($9.0 billion charge) and Terns Pharmaceuticals ($5.7 billion charge), impacting the bottom line for the period. Despite the net loss, operational cash flow remained strong at $15.8 billion. The company also continues to manage market access and pricing pressures globally, with specific impacts from the Inflation Reduction Act on key products like Januvia and Janumet. The balance sheet shows a decrease in cash and cash equivalents to $9.55 billion from $14.57 billion at the end of 2025, alongside an increase in long-term debt to $49.69 billion. This reflects the significant investment in business development activities during the period. Merck continues to invest heavily in its pipeline, evidenced by the substantial R&D expenses and the strategic acquisitions aimed at bolstering its oncology and infectious disease portfolios. Investors should monitor the successful integration of these acquisitions and the performance of Keytruda and other key products amidst ongoing pricing and regulatory challenges.
Merck 8-K Report, Financial Results (Oct 29, 2026)
Merck & Co., Inc. (MRK) reported strong third-quarter 2026 financial results, driven by continued robust sales growth in its oncology and animal health segments, alongside contributions from other key products like WINREVAIR. Total worldwide sales reached $18.1 billion, a 5% increase year-over-year, with KEYTRUDA and KEYTRUDA QLEX sales showing a significant 6% rise to $8.6 billion. WINREVAIR demonstrated exceptional growth, soaring by 93% to $694 million. The company also highlighted substantial progress in its diverse pipeline, particularly in oncology, with key data presentations at the ESMO Congress 2026 and regulatory milestones such as the U.S. FDA's acceptance of a priority review for sacituzumab tirumotecan (sac-TMT) in endometrial cancer. Merck has narrowed and raised its full-year 2026 financial outlook, now expecting sales between $66.8 billion and $67.3 billion and non-GAAP EPS between $2.77 and $2.82, reflecting confidence in its ongoing growth trajectory and pipeline advancements.
Merck 8-K Report, Executive Changes (Oct 13, 2026)
Merck & Co., Inc. (NYSE: MRK) filed a Form 8-K on October 13, 2026 to report the election of Paul J. Diaz to its Board of Directors, effective November 1, 2026. Diaz, a managing partner at Cressey & Company and former CEO of Myriad Genetics and Kindred Healthcare, will join the Audit Committee and the Research Committee. With his addition, the board will grow to 14 members, and he will stand for shareholder election at the May 2027 annual meeting. For investors, this is a governance-level event rather than a financial one. The filing contains no earnings, guidance, financing, or material operational disclosures. The appointment of an experienced healthcare executive to the Audit Committee is a modest positive for board oversight of financial reporting and internal controls, and his seat on the Research Committee adds healthcare leadership experience to oversight of the company's pipeline. Diaz's compensation will follow Merck's standard non-employee director program, as described in the April 8, 2026 proxy statement, so no new compensation arrangement was disclosed. The company also states that Diaz has no arrangements or understandings with any other person regarding his election and no related-party transactions requiring disclosure under Item 404(a) of Regulation S-K. Overall, the filing is routine and unlikely to have a direct effect on the stock price or the company's near-term financial outlook.
Merck Quarterly Report for Q2 Ended Jun 30, 2026
Merck & Co., Inc. reported a net loss of $1.335 billion for the second quarter of 2026, a significant shift from the $4.427 billion net income reported in the same period of the prior year. This loss, equating to $0.54 per share, is largely attributable to substantial investments in research and development, particularly the significant charges related to the acquisitions of Terns Pharmaceuticals, Inc. ($5.7 billion) and Cidara Therapeutics, Inc. ($9.0 billion). Despite the quarterly loss, total sales showed a modest increase of 5% year-over-year to $16.6 billion, driven by strong performance in oncology, notably Keytruda, and the Animal Health segment. The company's strategic acquisitions aim to bolster its pipeline and future growth, but have created near-term pressure on profitability. For the first six months of 2026, Merck reported a net loss of $5.575 billion compared to a net income of $9.506 billion in the prior year. This widening loss is also heavily influenced by the substantial R&D expenses from acquisitions. The balance sheet reflects a significant decrease in cash and cash equivalents, from $14.565 billion at the end of 2025 to $6.849 billion at June 30, 2026, due in part to funding these acquisitions. While the company faces profitability headwinds in the short term due to these strategic investments, the continued growth in key pharmaceutical products and the Animal Health division signal underlying operational strength.
Merck 8-K Report, Financial Results (Aug 4, 2026)
Merck & Co. (MRK) reported second-quarter 2026 results on August 4, 2026, with worldwide sales of $16.6 billion, up 5% (4% excluding FX). Growth was led by KEYTRUDA/KEYTRUDA QLEX ($8.4 billion, up 5%, including $463 million of initial KEYTRUDA QLEX sales), WINREVAIR ($588 million, up 75%), and Animal Health ($1.8 billion, up 8%). Gross margin compressed on a GAAP basis to 73.5% from 77.5%, and non-GAAP to 81.1% from 82.2%, reflecting higher amortization and inventory write-downs. The headline result was a GAAP loss of $0.54 per share and a non-GAAP loss of $0.13 per share, driven by a $2.31 per share (about $5.7 billion) one-time R&D charge for the acquisition of Terns Pharmaceuticals, which carried no tax benefit. The full-year 2026 sales outlook was narrowed and raised to $66.3-$67.3 billion from $65.8-$67.0 billion. Non-GAAP EPS guidance, however, fell sharply to $2.66-$2.76 from $5.04-$5.16. That reduction reflects one-time charges of $3.62 per share for the Cidara acquisition and $2.31 per share for Terns, plus about $0.12 per share of financing and MK-4208 advancement costs. The non-GAAP effective tax rate guidance rose to 35.0%-36.0% from 23.5%-24.5%, because the acquisition charges are not tax-deductible. Non-GAAP operating expenses are now guided to $42.0-$42.7 billion, up from $36.0-$36.8 billion, largely due to these one-time R&D charges. Pipeline news was substantial. The FDA approved LIPFENDRA (enlicitide), the first once-daily oral PCSK9 inhibitor, and several KEYTRUDA combination approvals were granted. The company also announced positive Phase 3 TroFuse-005 data for sac-TMT in endometrial cancer and positive ATLAS-UC data for tulisokibart, while the tulisokibart SSc-ILD study failed its primary endpoint and will be discontinued. Investors should weigh strong top-line and launch momentum against the sharp near-term EPS reset, the continued KEYTRUDA patent-cycle transition, and the ongoing cost of business development.
Merck 8-K Report, Shareholder Vote Results (May 28, 2026)
This 8-K filing from Merck & Co., Inc. (MRK) reports on the outcomes of its Annual Meeting of Shareholders held on May 26, 2026. The primary focus of the filing is the voting results on several key corporate matters. Importantly, all director nominees were elected by a substantial majority of votes cast, indicating continued shareholder confidence in the current board's leadership. Shareholders also approved the compensation of named executive officers on a non-binding advisory basis and ratified the appointment of the company's independent registered public accounting firm for 2026, with strong support for both proposals. However, the filing also highlights shareholder sentiment on ESG-related matters. Two shareholder proposals, one concerning a report on DEI risks in federal contracting and another on healthcare coverage gaps, received a very small percentage of 'FOR' votes relative to 'AGAINST' votes, suggesting limited shareholder backing for these specific initiatives at this time. Similarly, a proposal regarding political contributions also saw a significant majority vote against it. Investors should note the strong approval for governance and executive compensation matters, alongside the clear shareholder rejection of the presented ESG-focused proposals.
Merck 8-K Report, Corporate Update (May 22, 2026)
Merck & Co., Inc. (MRK) has filed an 8-K report detailing the successful closing of a significant underwritten public offering of various debt securities on May 22, 2026. The offering collectively raised substantial capital through the issuance of Floating Rate Notes due 2028 and fixed-rate notes maturing in 2028, 2031, 2033, 2036, 2046, and 2056, with aggregate principal amounts totaling $7.0 billion. This debt issuance, conducted under Merck's existing shelf registration statement, indicates the company's proactive capital management and its ability to access public debt markets to fund its operations, potential investments, or refinance existing obligations. The diverse maturity profile of the notes suggests a strategy to manage its debt obligations over the long term and potentially take advantage of prevailing interest rate conditions. Investors should monitor how these funds are deployed and their impact on Merck's financial leverage and future growth initiatives.
Merck Quarterly Report for Q1 Ended Mar 31, 2026
Merck & Co., Inc. reported a net loss of $4.24 billion ($1.72 per share) for the first quarter of 2026, a significant reversal from the $5.08 billion net income ($2.01 per share) reported in the same period of 2025. This loss was largely driven by a substantial increase in Research and Development (R&D) expenses, primarily due to the $9.2 billion acquisition of Cidara Therapeutics and an anticipated $5.8 billion charge from the pending acquisition of Terns Pharmaceuticals. Despite the reported net loss, the company's sales showed resilience, growing 5% to $16.3 billion year-over-year, supported by strong performance in oncology, particularly Keytruda, and the Animal Health segment. However, the significant R&D investments, coupled with ongoing restructuring costs and pressures on drug pricing due to regulatory changes like the Inflation Reduction Act, present a challenging near-term outlook. Investors should closely monitor the integration of recent acquisitions and the impact of evolving healthcare policies on future profitability.
Merck 8-K Report, Financial Results (Apr 30, 2026)
Merck & Co. (MRK) reported first-quarter 2026 sales of $16.3 billion, up 5% reported and 3% excluding foreign exchange, driven by Keytruda/Keytruda Qlex ($8.0 billion, up 12%), WINREVAIR ($525 million, up 88%), and Animal Health ($1.8 billion, up 13%). However, GAAP and non-GAAP results were heavily depressed by a one-time $9.0 billion charge ($3.62 per share) for the acquisition of Cidara Therapeutics, producing a GAAP loss per share of $1.72 and a non-GAAP loss per share of $1.28, compared with GAAP EPS of $2.01 and non-GAAP EPS of $2.22 a year earlier. Excluding the Cidara charge, the underlying business trends are more meaningful: non-GAAP gross margin was 81.9% versus 82.2%, and continued growth in oncology, cardiometabolic, and animal health offset declines in Gardasil (down 19%, largely on lower China demand), Januvia/Janumet (down 28%), and Lagevrio (down 73%). Management narrowed and raised the midpoint of its full-year 2026 guidance, now calling for sales of $65.8 billion to $67.0 billion (prior $65.5 billion to $67.0 billion) and non-GAAP EPS of $5.04 to $5.16 (prior $5.00 to $5.15), both including the Cidara charge. Importantly, the outlook excludes the pending acquisition of Terns Pharmaceuticals, which is expected to close in May 2026 and carry a one-time charge of approximately $5.8 billion, or about $2.35 per share, plus an estimated $0.12 per share of further EPS drag over the remainder of 2026 from TERN-701 investment and financing costs. Investors will need to weigh this near-term earnings dilution against the strategic push to diversify the portfolio beyond Keytruda, which faces biosimilar and patent-cycle risks over time. Pipeline news was mixed. Positive developments included FDA approval of IDVYNSO (an oral once-daily HIV regimen), approval of Keytruda for platinum-resistant ovarian cancer, and positive Phase 3 KEYNOTE-B15 results with a priority review (PDUFA August 17, 2026). Setbacks included several Phase 3 readouts that failed to reach statistical significance, notably LITESPARK-012 in renal cell carcinoma, KEYNOTE-975 in esophageal cancer, and KEYNOTE-866 in muscle-invasive bladder cancer. Upcoming catalysts include multiple PDUFA dates in June, August, and October 2026 and an Oncology Investor Event on June 1, 2026.
Merck Annual Report, Year Ended Dec 31, 2025
Merck & Co., Inc. reported total sales of $65.0 billion for the fiscal year 2025, a modest 1% increase year-over-year (2% excluding foreign exchange impact). This growth was primarily driven by strong performance in the oncology franchise, particularly Keytruda, and the Animal Health segment, alongside contributions from the cardiometabolic and respiratory portfolio, including the launch of Winrevair, and the acquisition of Verona Pharma which added Ohtuvayre. However, the company faced headwinds in its vaccines segment, notably a significant decline in Gardasil/Gardasil 9 sales in China due to inventory issues and local competition, as well as lower sales in the immunology and virology segments. Merck continued to bolster its pipeline through strategic business development, including the acquisition of Cidara Therapeutics and Verona Pharma, and exclusive license agreements for promising early-stage candidates. The company also advanced its late-stage pipeline with numerous regulatory submissions and positive Phase 3 trial results across various therapeutic areas. Despite revenue growth, the company announced a significant restructuring program aimed at optimizing operations and supporting future growth, expected to result in annual cost savings. Investors should monitor upcoming patent expirations for key products like Januvia and Janumet, and the ongoing impact of regulatory changes and pricing pressures, particularly from the Inflation Reduction Act, which is expected to affect Keytruda's U.S. sales in the future.
Merck 8-K Report, Financial Results (Feb 3, 2026)
Merck & Co. (MRK) reported fourth-quarter and full-year 2025 results on February 3, 2026. Fourth-quarter worldwide sales were $16.4 billion, up 5% (4% ex-FX), while full-year sales were $65.0 billion, up 1% (2% ex-FX). Growth was led by KEYTRUDA/KEYTRUDA QLEX ($31.7 billion, up 7%) and newer launches including WINREVAIR ($1.4 billion, up from $419 million) and CAPVAXIVE ($759 million). These gains were offset by a 39% decline in GARDASIL/GARDASIL 9 to $5.2 billion, driven by lower China demand and Japan's catch-up program. Animal Health grew 8% to $6.4 billion. Full-year non-GAAP EPS was $8.98 (up 17%) and GAAP EPS was $7.28 (up 8%), with the GAAP figure absorbing a $0.20 per-share charge for business development deals. The more consequential news for investors is the 2026 outlook. Merck guided to sales of $65.5 to $67.0 billion and non-GAAP EPS of $5.00 to $5.15. That EPS guide is sharply lower than 2025 because it includes a one-time charge of roughly $3.65 per share (about $9.0 billion) tied to the acquisition of Cidara Therapeutics, plus about $0.30 per share of related financing and operating costs. Excluding the Cidara charge, the implied underlying earnings trajectory is considerably more stable. The outlook also assumes no additional significant business development transactions, which is consistent with Merck's past practice. Management highlighted pipeline progress, including 18 positive Phase 3 readouts in 2025, FDA Commissioner's National Priority Vouchers for enlicitide and sac-TMT, and a U.S. government agreement that delays Section 232 tariffs for three years in exchange for more than $70 billion in committed U.S. capital and R&D spending. Key risks for investors are the continued erosion of GARDASIL, KEYTRUDA's dependence on its ongoing lifecycle and the timing of its loss of exclusivity, the rising interest expense and FX losses that pushed other expense higher, and the execution risk of integrating Verona Pharma and Cidara. Because this filing furnishes the press release under Item 2.02, the content is not deemed filed under Section 18 of the Exchange Act.
Merck 8-K Report, Corporate Update (Dec 4, 2025)
Merck & Co., Inc. (MRK) announced the successful closing of a significant underwritten public offering of debt securities on December 4, 2025. The offering comprised a total of eight distinct tranches of notes, raising a substantial amount of capital for the company. This move indicates Merck's strategy to secure long-term financing and potentially fund its ongoing research and development, capital expenditures, or general corporate purposes. The issuance involved notes with varying maturity dates, ranging from 2029 to 2065, and a mix of floating rate and fixed-rate instruments, suggesting a diversified approach to debt management. Investors should note that this offering represents a material increase in Merck's outstanding debt. While the specific use of proceeds is not detailed in this 8-K filing, such debt issuances are typically aimed at strengthening the company's financial flexibility and supporting its strategic initiatives. The diverse maturity profile suggests an effort to manage interest rate risk and balance short-term and long-term financing needs. Further analysis of Merck's financial statements and future disclosures will be necessary to fully understand the impact of this debt issuance on the company's capital structure and profitability.
Merck Quarterly Report for Q3 Ended Sep 30, 2025
Merck & Co., Inc. reported a strong financial performance for the third quarter and first nine months of 2025, with total sales reaching $17.3 billion and $48.6 billion, respectively. This represents a 4% increase year-over-year for the quarter and a slight increase for the nine-month period. The company experienced significant growth in its Pharmaceutical segment, driven by Keytruda, Welireg, and alliance revenues from Lynparza and Lenvima, alongside the cardiovascular franchise boosted by the Winrevair launch. The Animal Health segment also showed robust growth. Despite strong sales, R&D expenses saw a notable decrease of 28% in Q3 and 11% year-to-date, primarily due to reduced business development activity compared to the prior year's significant acquisition-related charges. The company also initiated a new restructuring program expected to yield substantial cost savings. Key strategic moves during the period include the significant acquisition of Verona Pharma for approximately $10.5 billion, bolstering the respiratory disease portfolio with Ohtuvayre, and entering a funding arrangement with Blackstone for the development of sacituzumab tirumotecan. These strategic investments underscore Merck's commitment to expanding its therapeutic reach. While overall sales show positive momentum, the company faces ongoing pricing pressures and evolving regulatory landscapes, particularly from the Inflation Reduction Act's drug price negotiation program impacting products like Januvia and Janumet. Legal proceedings, including the Gardasil litigation, continue, though a proposed agreement to resolve the bulk of pending claims was reached, which is expected to be not material to Merck.
Merck 8-K Report, Financial Results (Oct 30, 2025)
Merck & Co. (MRK) reported third-quarter 2025 results with total sales of $17.3 billion, up 4% nominally and 3% excluding foreign exchange. Growth was led by KEYTRUDA, which rose 10% to $8.1 billion (8% ex-FX), and WINREVAIR, which more than doubled to $360 million. GAAP EPS was $2.32 and non-GAAP EPS was $2.58, with both including a $0.10 per-share charge for a milestone payment to LaNova tied to the MK-2010 technology transfer. GAAP net income rose 83% year over year, though that comparison benefits from a 2024 quarter that carried roughly $0.79 per share in aggregate business development charges (EyeBio, MK-1045/Curon, and a Daiichi Sankyo-related item). Gross margin expanded to 77.7% GAAP and 81.9% non-GAAP. GARDASIL/GARDASIL 9 was the main drag, falling 24% to $1.7 billion on lower demand in China, and LAGEVRIO declined 64%. Management raised and narrowed its full-year 2025 non-GAAP EPS guidance to $8.93–$8.98 from $8.87–$8.97, and raised the sales outlook to $64.5–$65.0 billion from $64.3–$65.3 billion. The EPS raise reflects a roughly $0.09 benefit from an amended AstraZeneca Koselugo agreement and operational improvements, partly offset by about $0.04 of dilution from the Verona Pharma acquisition, which closed in October 2025. Management also reiterated a commitment of more than $70 billion to U.S. manufacturing and R&D beginning in 2025, excluding future business development. For investors, the key takeaways are the strong KEYTRUDA franchise (with a subcutaneous KEYTRUDA QLEX now approved across solid tumor indications), the rapid WINREVAIR ramp, and the Verona and Koselugo-related guidance changes. Offsetting these are the GARDASIL China decline and the ongoing exposure to a patent cliff for KEYTRUDA in the later part of the decade, which the filing does not discuss directly. The updated guidance does not assume additional significant business development transactions, and management plans an investor event at AHA on November 9, 2025.
Merck 8-K Report, Corporate Update (Sep 9, 2025)
Merck & Co., Inc. (MRK) announced the successful closing of a substantial underwritten public offering of debt securities on September 9, 2025. This offering comprises various tranches of notes with aggregate principal amounts totaling $6.5 billion, including floating rate notes and fixed-rate notes with maturities ranging from 2027 to 2055. The proceeds from this offering will likely be used to fund general corporate purposes, potentially including research and development, acquisitions, or refinancing existing debt. Investors should note that this issuance increases the company's overall debt leverage. The issuance was conducted under the company's effective Form S-3ASR registration statement, indicating Merck's established access to capital markets. The specific terms of the notes, including coupon rates and maturity dates, are detailed in the filing. The inclusion of various maturity dates suggests a strategy to manage interest rate risk and maintain a balanced debt maturity profile. Investors will want to monitor how these new debt obligations impact Merck's financial leverage ratios and cash flow from operations.
Merck Quarterly Report for Q2 Ended Jun 30, 2025
Merck & Co., Inc. reported mixed financial results for the quarter ended June 30, 2025. Total sales decreased by 2% to $15.8 billion compared to the prior year, primarily driven by lower vaccine and virology sales, partially offset by growth in oncology and cardiovascular segments. Net income attributable to Merck & Co., Inc. also saw a decline, falling to $4.4 billion from $5.5 billion in the same period last year, resulting in diluted earnings per share of $1.76, down from $2.14. Despite the top-line decline, the company announced a significant strategic move with an agreement to acquire Verona Pharma plc for approximately $10 billion to bolster its respiratory portfolio. Research and development expenses increased by 16% to $4.0 billion, driven by an upfront payment for a new license agreement and increased clinical development spending. Restructuring costs were also substantial, reflecting a new $3 billion restructuring program aimed at driving future growth and efficiency.
Merck 8-K Report, Financial Results (Jul 29, 2025)
Merck (MRK) reported second-quarter 2025 results on July 29, 2025, with total sales of $15.8 billion, down 2% both nominally and excluding foreign exchange. The top-line decline was driven by Gardasil/Gardasil 9, which fell 55% to $1.1 billion on lower demand in China, and by the absence of SIMPONI, which reverted to Johnson & Johnson in October 2024. KEYTRUDA was the standout performer at $8.0 billion, up 9%, and WINREVAIR reached $336 million as it continued its U.S. launch. Animal Health grew 11% to $1.6 billion. GAAP EPS was $1.76 and non-GAAP EPS was $2.13, versus $2.14 and $2.28 a year earlier. Both figures include a $0.07 charge for the Hengrui Pharma license closing. The most consequential disclosure is the new multiyear optimization initiative, which targets roughly $3.0 billion in annual cost savings by the end of 2027, to be fully reinvested in growth areas. Within it, a 2025 Restructuring Program carries cumulative pretax costs of about $3.0 billion (roughly 60% cash) and is expected to deliver $1.7 billion of annual savings, largely realized by end-2027. Merck recorded $649 million of restructuring charges related to this program in Q2. Management also narrowed full-year 2025 guidance: sales of $64.3 to $65.3 billion and non-GAAP EPS of $8.87 to $8.97, which includes about $0.16 of one-time charges. The outlook excludes the pending Verona Pharma acquisition, expected to close in Q4 2025 for about $10 billion. Investors should weigh the strong KEYTRUDA and pipeline momentum against the Gardasil erosion and the near-term cost of the restructuring. Pipeline news in the quarter was mixed. Several Phase 3 readouts were positive, including the CORALreef trials of enlicitide and KEYNOTE-B96, but KEYNOTE-937 and LEAP-014 did not reach statistical significance. Upcoming catalysts include the WINREVAIR label-update PDUFA date of October 25, 2025, and the doravirine/islatravir PDUFA date of April 28, 2026.
Merck 8-K Report, Shareholder Vote Results (May 29, 2025)
Merck & Co., Inc. (MRK) has filed an 8-K report detailing the results of its Annual Meeting of Shareholders held on May 27, 2025. The filing primarily focuses on the voting outcomes of several key proposals presented to shareholders. All director nominees were overwhelmingly elected, indicating strong shareholder confidence in the current board's composition and leadership. Similarly, the appointment of the Company's independent registered public accounting firm for 2025 received substantial ratification. Notably, the advisory vote to approve the compensation of named executive officers also passed with significant support. However, several shareholder proposals, including those related to human rights impact assessments, tax transparency, revisiting DEI goals in executive pay, and civil liberties in advertising, did not receive majority support and were voted down. These outcomes suggest shareholders are largely aligned with the company's current governance and executive compensation practices, while also signaling a divergence of opinion on specific ESG-related initiatives proposed by shareholders.
Merck Quarterly Report for Q1 Ended Mar 31, 2025
Merck & Co., Inc. reported its first-quarter 2025 financial results, showing a slight year-over-year decrease in total sales to $15.5 billion from $15.8 billion in Q1 2024. This decline was primarily driven by lower vaccine sales, particularly Gardasil/Gardasil 9, and reduced sales in the virology and immunology segments. However, the company saw growth in its oncology, cardiovascular, and diabetes franchises, supported by strong performance from Keytruda and the new cardiovascular drug Winrevair. Despite the overall sales dip, Merck's profitability improved, with Net Income increasing to $5.1 billion from $4.8 billion year-over-year, leading to a rise in diluted Earnings Per Share (EPS) to $2.01 from $1.87. Research and Development expenses saw a notable decrease, primarily due to a significant charge in the prior year related to the acquisition of Harpoon Therapeutics. The company also announced a new licensing agreement for an investigational oral small molecule Lipoprotein(a) inhibitor and acquired a manufacturing facility in Ireland, signaling continued strategic investment in its pipeline and operational capabilities.
Merck 8-K Report, Financial Results (Apr 24, 2025)
Merck reported first-quarter 2025 results on April 24, 2025, with worldwide sales of $15.5 billion, down 2% from the prior year but up 1% excluding foreign exchange. The top-line picture was mixed: KEYTRUDA grew 4% to $7.2 billion (6% ex-FX) and WINREVAIR launched to $280 million in its first full year of U.S. uptake, while GARDASIL/GARDASIL 9 fell 41% to $1.3 billion, driven mainly by lower demand in China. Animal Health (+5%) and Other Revenues (+17%, helped by out-licensing payments) were bright spots. Profitability held up well, with GAAP EPS of $2.01 (up 7%) and non-GAAP EPS of $2.22 (up 7%, or 12% ex-FX). Non-GAAP gross margin improved to 82.2% from 81.2%. Management maintained full-year 2025 sales guidance of $64.1 billion to $65.6 billion, but lowered non-GAAP EPS guidance to $8.82 to $8.97 from $8.88 to $9.03. The cut reflects a one-time charge of about $0.06 per share tied to an upfront payment for the exclusive license of Hengrui Pharma's oral Lp(a) inhibitor, expected to close in the second quarter of 2025. Excluding that charge, the EPS outlook would have been unchanged. The outlook also absorbs roughly $200 million of incremental tariff costs and about 1% of negative FX impact on sales. Guidance continues to include an expected $0.09 per share charge tied to the LaNova MK-2010 technology-transfer milestone. For investors, the key items to monitor are the trajectory of GARDASIL in China, the pace of WINREVAIR and KEYTRUDA uptake, upcoming regulatory decisions (subcutaneous pembrolizumab PDUFA date of September 23, 2025, and KEYNOTE-689 head and neck PDUFA date of June 23, 2025), and the execution of Merck's pipeline business development and U.S. manufacturing investments. The company's guidance does not assume additional significant business development deals.
Merck Annual Report, Year Ended Dec 31, 2024
Merck & Co., Inc. (MRK) reported robust sales growth of 7% to $64.2 billion in 2024, driven primarily by strong performance in oncology, cardiovascular, and animal health sectors. The company's flagship oncology drug, Keytruda, saw a significant 18% increase in global sales, reaching $29.5 billion and demonstrating continued strong demand across numerous indications and earlier-stage cancer treatments. The animal health segment also contributed positively with a 4% sales increase. Despite overall growth, the company experienced a decline in its diabetes franchise due to competitive pressures and Januvia/Janumet patent expirations, as well as reduced sales of Lagevrio (COVID-19 medication) and a notable dip in Gardasil/Gardasil 9 sales in China, a trend expected to continue into 2025. Merck actively pursued strategic business development, including several key acquisitions and licensing agreements in the ophthalmology, immunotherapy, and oncology spaces, bolstering its pipeline. The company also advanced its regulatory submissions and secured numerous product approvals globally throughout 2024, highlighting its ongoing commitment to innovation and addressing unmet medical needs. Looking ahead, Merck faces potential headwinds from pricing pressures and government regulations, notably the Inflation Reduction Act (IRA), which is expected to impact Keytruda's U.S. sales in the future. However, the company's diversified portfolio, strong pipeline, and strategic business development initiatives position it for continued growth. Investors should monitor developments in Keytruda's market exclusivity, the impact of the IRA on pricing, and the success of new product launches and pipeline advancements, particularly in oncology and cardiovascular diseases.
Merck 8-K Report, Financial Results (Feb 4, 2025)
Merck & Co. (MRK) reported fourth-quarter and full-year 2024 results on February 4, 2025, showing strong top-line momentum led by KEYTRUDA. Fourth-quarter worldwide sales rose 7% to $15.6 billion (9% excluding foreign exchange), and full-year sales grew 7% to $64.2 billion (10% ex-FX). KEYTRUDA was the standout, with full-year sales up 18% to $29.5 billion, while GARDASIL/GARDASIL 9 declined 3% to $8.6 billion, driven largely by weaker demand in China. WINREVAIR launched in the second quarter of 2024 and reached $419 million in its first partial year, and Animal Health grew 4% to $5.9 billion. GAAP results were distorted by business development charges. Full-year GAAP EPS was $6.74 and non-GAAP EPS was $7.65, both including a net $1.28 per-share charge tied to licensing deals and collaborations. Fourth-quarter GAAP EPS was $1.48 and non-GAAP EPS was $1.72, including a $0.23 charge tied to the LaNova and Hansoh agreements. Year-over-year comparisons are heavily affected by the prior year's large charges and the 2023 Zetia settlement, so the non-GAAP figures are the more useful measure of underlying performance. Margin expansion was notable: non-GAAP gross margin reached 80.8% in both the fourth quarter and full year, reflecting favorable product mix, including lower royalty rates on KEYTRUDA and GARDASIL. For 2025, Merck guided to sales of $64.1 billion to $65.6 billion and non-GAAP EPS of $8.88 to $9.03. The outlook includes a roughly $0.09 per-share one-time charge for a $300 million LaNova milestone payment, and it reflects a temporary pause in GARDASIL shipments to China starting February 2025 through at least mid-year. The guidance also excludes any significant new business development deals, consistent with past practice. Pipeline news included positive ZENITH results for WINREVAIR (stopped early for overwhelming efficacy), positive Phase 3 data for subcutaneous pembrolizumab, and an FDA BLA acceptance for clesrovimab with a June 10, 2025 PDUFA date.
Merck 8-K Report, Executive Changes (Nov 22, 2024)
Merck & Co. (MRK) filed an 8-K on November 22, 2024 reporting two governance actions rather than financial results. First, the company announced that Surendralal L. "Lal" Karsanbhai, president and CEO of Emerson Electric Co. (NYSE: EMR), will join its Board of Directors effective January 1, 2025, expanding the board to 13 members. He will be appointed to both the Audit and Governance Committees and will stand for shareholder election in May 2025. He will receive standard non-employee director compensation, and the filing discloses no related-party transactions or special election arrangements. Second, on November 19, 2024, the Board adopted amended and restated by-laws that revise and update indemnification provisions for directors, officers, employees and agents, along with some non-substantive conforming changes. The filing describes these as updates to indemnification terms rather than changes to shareholder rights or corporate control provisions, though investors should review the full By-Laws (Exhibit 3.1) to confirm the specifics. For investors, neither item affects Merck's reported financials or guidance. The most notable element is the addition of an experienced industrial operator with audit committee responsibilities, which may be viewed as a positive for board oversight and operational perspective. The filing also contains standard forward-looking statement cautions referencing the company's 2023 Form 10-K.
Merck Quarterly Report for Q3 Ended Sep 30, 2024
Merck & Co., Inc. reported solid financial results for the third quarter and the first nine months of 2024. Total sales increased by 4% year-over-year to $16.7 billion in the third quarter and by 7% to $48.5 billion for the nine-month period. This growth was primarily driven by strong performance in the oncology franchise, notably Keytruda, and contributions from the cardiovascular and animal health segments. Despite overall sales growth, the company faced some headwinds, including a decline in vaccine sales, particularly Gardasil/Gardasil 9 due to lower demand in China. Additionally, sales of key diabetes medications like Januvia and Janumet continued to decline due to loss of exclusivity and pricing pressures. Research and Development expenses saw a significant increase, largely due to substantial charges from recent acquisitions, including EyeBio and MK-1045, impacting reported profitability. However, non-GAAP income remained strong, reflecting operational performance excluding these acquisition-related costs.
Merck 8-K Report, Financial Results (Oct 31, 2024)
Merck's third-quarter 2024 results (8-K filed October 31, 2024) showed total sales of $16.7 billion, up 4% reported and 7% excluding foreign exchange, led by KEYTRUDA, which grew 17% to $7.4 billion (21% ex-FX). Growth was partially offset by declines in GARDASIL/GARDASIL 9 (down 11%, largely on lower demand in China), JANUVIA/JANUMET (down 42%) and LAGEVRIO (down 40%). Animal Health sales rose 6% to $1.5 billion, and WINREVAIR, launched in the U.S. in the second quarter, reached $149 million in sales. Earnings were depressed by business development charges. GAAP EPS was $1.24 versus $1.86 a year earlier, and non-GAAP EPS was $1.57 versus $2.13, with both figures including a net $0.79 per-share charge tied to the EyeBio and Curon acquisitions and a Daiichi Sankyo payment. Non-GAAP gross margin improved to 80.5% from 77.0%, reflecting favorable product mix and lower royalty rates on KEYTRUDA and GARDASIL. Full-year 2024 guidance was mixed. Sales guidance was narrowed to $63.6 to $64.1 billion from $63.4 to $64.4 billion, and the non-GAAP EPS range was lowered to $7.72 to $7.77 from $7.94 to $8.04, reflecting a net $0.24 per-share negative impact from the Curon and Daiichi Sankyo transactions. Management said the outlook assumes no additional significant business development transactions.
Merck Quarterly Report for Q2 Ended Jun 30, 2024
Merck & Co., Inc. reported strong financial results for the quarter and six months ended June 30, 2024. Sales increased by 7% to $16.1 billion in the second quarter and 8% to $31.9 billion year-to-date, driven primarily by growth in the oncology and vaccines segments, particularly from Keytruda and Gardasil/Gardasil 9. Net income attributable to Merck & Co., Inc. significantly improved to $5.5 billion ($2.15 per share) in the second quarter, compared to a net loss of $6.0 billion ($2.35 per share) in the prior year period. This turnaround is largely due to the absence of substantial acquisition-related charges that impacted the prior year. The company continued its strategic growth through significant business development, including the acquisition of Elanco's aqua business and EyeBio in July 2024, and Harpoon Therapeutics in March 2024. These investments, while impacting R&D expenses, are positioned to bolster the company's pipeline and future growth. Merck also announced a new $4.0 billion restructuring program aimed at optimizing its manufacturing network, expected to yield substantial annual cost savings by 2031. The company's liquidity remains strong, with robust operating cash flow supporting its strategic initiatives and shareholder returns, including dividends and share repurchases.
Merck 8-K Report, Financial Results (Jul 30, 2024)
Merck reported second-quarter 2024 results on July 30, 2024, with total sales of $16.1 billion, up 7% reported and 11% excluding foreign exchange. KEYTRUDA was the clear growth engine at $7.3 billion (up 16%, or 21% ex-FX), driven by earlier-stage indications such as triple-negative breast cancer and renal cell carcinoma. Profitability was strong: GAAP EPS was $2.14 versus a loss of $2.35 a year earlier, which included a $4.02 per share Prometheus charge, and non-GAAP EPS was $2.28. The quarter also benefited from a $259 million tax reserve release tied to the expiration of a statute of limitations for the 2019 tax year, which flattered the GAAP and non-GAAP tax lines and should be treated as non-recurring. The full-year 2024 sales outlook was raised and narrowed to $63.4 to $64.4 billion from $63.1 to $64.3 billion, despite a softer quarter for GARDASIL in China caused by distributor sell-out timing. However, non-GAAP EPS guidance was cut sharply to $7.94 to $8.04 from $8.53 to $8.65. The reduction reflects a one-time $1.3 billion (about $0.51 per share) charge for the EyeBio acquisition, plus about $0.26 per share for Harpoon and roughly $0.09 per share of financing and asset-advancement expense, and a higher expected non-GAAP tax rate of 15.5% to 16.5%. Investors should therefore read the EPS cut as largely acquisition-driven rather than a deterioration in underlying demand. On the pipeline side, the filing highlights the U.S. launch of WINREVAIR (over 1,000 patients treated by end of June), FDA approval of the CAPVAXIVE pneumococcal vaccine with a unanimous ACIP recommendation, positive Phase 2b/3 data for clesrovimab in infant RSV prevention, and a positive EU CHMP opinion for WINREVAIR. Offsetting pressures include continued erosion in JANUVIA/JANUMET (down 27% and 27% in the quarter, respectively, on U.S. pricing and generic competition), BRIDION, and LAGEVRIO, as well as the Argentine peso devaluation that weighed on reported growth.
Merck 8-K Report, Shareholder Vote Results (May 30, 2024)
Merck & Co., Inc. (MRK) filed an 8-K on May 29, 2024, detailing the results of its Annual Meeting of Shareholders held on May 28, 2024, and the closing of a significant debt offering. The shareholder meeting saw overwhelming approval for the election of all director nominees, the executive compensation plan (say-on-pay), and the ratification of the independent auditor. These strong votes indicate continued shareholder confidence in the company's leadership and financial oversight. In addition to the shareholder meeting outcomes, Merck announced on May 30, 2024, the successful closing of a public offering of €3.4 billion in aggregate principal amount of notes across four maturity tranches (2032, 2037, 2044, and 2054) by its subsidiary, MSD Netherlands Capital B.V. These notes are fully guaranteed by Merck & Co., Inc. This debt issuance provides the company with substantial capital, likely for general corporate purposes or strategic initiatives, and diversifies its funding sources. Investors should note the relatively low interest rates on these long-term notes, reflecting favorable market conditions for the company.
Merck Quarterly Report for Q1 Ended Mar 31, 2024
Merck & Co., Inc. (MRK) reported strong first-quarter 2024 results, with net income attributable to Merck & Co., Inc. rising to $4.76 billion, or $1.87 per share, a significant increase from $2.82 billion, or $1.11 per share, in the prior year period. This performance was driven by a 9% increase in total sales, reaching $15.78 billion, bolstered by robust growth in the Oncology and Vaccines segments. Keytruda, Merck's flagship oncology drug, demonstrated substantial sales growth of 20%, and the Gardasil/Gardasil 9 HPV vaccines also saw significant increases. The company also continues to invest in its future through strategic acquisitions, notably the acquisition of Harpoon Therapeutics, Inc. and the pending acquisition of Elanco's aqua business, underscoring a commitment to pipeline expansion and innovation. Despite ongoing pricing pressures and the impact of foreign exchange, Merck's financial health remains strong, supported by effective cost management and a favorable product mix, positioning the company for continued growth.
Merck 8-K Report, Financial Results (Apr 25, 2024)
Merck reported first-quarter 2024 sales of $15.8 billion, up 9% from the prior year (12% excluding foreign exchange). Growth was led by oncology and vaccines: KEYTRUDA sales rose 20% to $6.9 billion (24% excluding FX), and GARDASIL/GARDASIL 9 rose 14% to $2.2 billion (17% excluding FX). Diabetes was the main drag, with JANUVIA/JANUMET down 24%. GAAP EPS was $1.87 and non-GAAP EPS was $2.07, both including a $0.26 per-share charge for the Harpoon acquisition. The GAAP gross margin improved to 77.6% from 72.9%, mainly from product mix, lower royalty rates on KEYTRUDA and GARDASIL, and lower amortization of intangibles. Management raised and narrowed its full-year 2024 outlook. Sales are now expected at $63.1 billion to $64.3 billion (previously $62.7 billion to $64.2 billion), and non-GAAP EPS at $8.53 to $8.65 (previously $8.44 to $8.59). The guidance includes roughly 3% negative FX impact on sales and about $0.30 per share of negative FX impact on EPS, largely attributable to the Argentine peso. The outlook does not assume additional significant business development deals. Merck also completed the Harpoon acquisition and agreed to acquire Elanco's aqua business, and WINREVAIR received FDA approval for pulmonary arterial hypertension. For investors, the key points are the strength of the KEYTRUDA franchise, the upward revision to earnings guidance, and the pipeline catalysts ahead. Three FDA target action dates fall in the second quarter of 2024 (V116, KEYTRUDA in endometrial cancer, and patritumab deruxtecan), and an Oncology Investor Event is scheduled for June 3, 2024. Risks include continued declines in the diabetes franchise, generic competition in Europe and Asia Pacific, currency volatility, and the possibility of additional business development charges that the outlook excludes.
Merck Annual Report (Amendment), Year Ended Dec 31, 2023
This filing is an amendment (10-K/A) to Merck & Co., Inc.'s annual report for the period ending December 30, 2023, filed on April 10, 2024. As this is a Part III and Part IV filing, it primarily incorporates by reference information from Merck's Proxy Statement for the May 28, 2024, Annual Shareholder Meeting and previously filed 10-K reports. Key information regarding directors, executive officers, corporate governance, and executive compensation is detailed within the referenced proxy statement, emphasizing adherence to a Code of Conduct and ethical business practices. Furthermore, the filing includes details on equity compensation plans, outlining the number of securities available for issuance and outstanding options as of December 31, 2023. It also lists various exhibits, including incorporation by reference of key corporate documents, indentures, and executive compensation plans, along with the necessary certifications from the CEO and CFO. Investors should refer to the referenced Proxy Statement for comprehensive details on governance and compensation practices.
Merck Annual Report, Year Ended Dec 31, 2023
Merck & Co., Inc. reported total sales of $60.1 billion for the fiscal year ended December 30, 2023, representing a 1% increase year-over-year (4% excluding foreign exchange impacts). This growth was primarily driven by strong performance in the oncology franchise, led by Keytruda, and the vaccines franchise, notably Gardasil/Gardasil 9. The company also saw increased alliance revenue from Lynparza and Lenvima, along with growth in hospital acute care and animal health products. However, these gains were partially offset by declines in the virology franchise, mainly due to lower sales of Lagevrio, and decreased sales in the diabetes segment from Januvia/Janumet. Merck continued to strengthen its pipeline and market position through strategic business development, including significant acquisitions such as Prometheus Biosciences and Imago BioSciences, and collaborations like the one with Daiichi Sankyo for antibody-drug conjugates. The company advanced numerous late-stage pipeline candidates and secured over 25 regulatory approvals in major markets during the year, highlighting continued innovation and expansion of its therapeutic offerings. Despite ongoing pricing pressures and global economic challenges, Merck remains focused on driving growth through its core therapeutic areas and expanding its reach in diverse markets.
Merck 8-K Report, Executive Changes (Feb 20, 2024)
Merck & Co., Inc. (MRK) filed an 8-K on February 20, 2024, reporting the upcoming retirement of a key board member. Peter C. Wendell, a director since 2002 and a member of the Audit Committee, has announced his intention to retire from the Board of Directors at the Company's 2024 Annual Meeting of Shareholders on May 28, 2024. This departure is not attributed to any disagreements with the company's operations, policies, or practices, which suggests a smooth transition. While the retirement of a long-serving director is noteworthy, investors should note that the filing explicitly states no disagreements exist. The primary focus for investors remains on Merck's ongoing business performance, its product pipeline, and strategic initiatives. The upcoming annual meeting will be a key event to watch for further updates on board composition and leadership.
Merck 8-K Report, Financial Results (Feb 1, 2024)
Merck (MRK) reported fourth-quarter and full-year 2023 results on February 1, 2024. Full-year 2023 sales were $60.1 billion, up 1% reported and 4% excluding foreign exchange, with Keytruda ($25.0 billion, up 19%) and Gardasil/Gardasil 9 ($8.9 billion, up 29%) driving growth, offset by a 75% decline in COVID-19 antiviral LAGEVRIO to $1.4 billion. Profitability was sharply lower on a GAAP basis: full-year GAAP EPS fell to $0.14 from $5.71, largely due to $6.21 per share of business development charges (including a $5.5 billion Daiichi Sankyo collaboration charge in Q4 and $11.4 billion across the Prometheus and Imago acquisitions). Non-GAAP EPS was $1.51 versus $7.48 in 2022. Excluding these charges, the underlying business showed improved gross margin (non-GAAP 76.9%, up from 74.4%) and operational strength. The company also disclosed a new 2024 Restructuring Program, approved January 29, 2024, with cumulative pretax costs of about $4.0 billion through the end of 2031. Roughly 60% is non-cash accelerated depreciation tied to facility closures or divestitures, and the rest is largely cash facility shutdown costs. The program targets Human Health manufacturing as the pipeline shifts to new modalities and Animal Health manufacturing efficiency. Only $190 million was recorded in 2023, so the bulk of the charge will fall in future periods. For 2024, Merck guided to sales of $62.7 to $64.2 billion and non-GAAP EPS of $8.44 to $8.59, which includes roughly $0.26 per share of one-time Harpoon acquisition charges and about $0.25 per share of foreign exchange headwind. Investors will focus on whether Keytruda and Gardasil growth can offset the expected LAGEVRIO decline, the pace of R&D spending tied to recent acquisitions, and the cash cost of the new restructuring program.
Merck 8-K Report, Executive Changes (Nov 28, 2023)
Merck & Co., Inc. (MRK) filed an 8-K on November 28, 2023, to announce a key executive transition within its finance department. Rita Karachun, Senior Vice President Finance – Global Controller and principal accounting officer, has resigned effective December 4, 2023, as she plans to retire in 2024. The company has assured investors that Ms. Karachun's departure is not a result of any disagreements concerning the company's operations, policies, or practices. Concurrently, Merck has appointed Dalton E. Smart III to succeed Ms. Karachun as Senior Vice President Finance – Global Controller and principal accounting officer, also effective December 4, 2023. Mr. Smart has a long tenure with Merck, most recently serving as Assistant Controller since September 2023 and previously holding roles in Internal Audit and Audit leadership. This transition appears to be an internal promotion, intended to ensure continuity in financial oversight.
Merck Quarterly Report for Q3 Ended Sep 30, 2023
Merck & Co., Inc. (MRK) reported solid third-quarter 2023 financial results, with total sales increasing by 7% year-over-year to $16.0 billion. This growth was primarily driven by strong performance in the oncology franchise, led by Keytruda, and robust sales from the vaccines franchise, particularly Gardasil 9. The company also saw positive contributions from the hospital acute care and cardiovascular segments. Despite overall sales growth, the company experienced a decline in the diabetes franchise due to increased competition and the impact of the Inflation Reduction Act on key products like Januvia. Operationally, the company recorded significant charges related to its strategic acquisitions of Prometheus Biosciences, Inc. ($10.2 billion) and Imago BioSciences, Inc. ($1.2 billion) in Research and Development expenses for the nine months ended September 29, 2023. This led to a substantial increase in R&D expenses for the period. The company also announced a significant global development and commercialization agreement with Daiichi Sankyo for three ADC candidates, which will result in a $5.5 billion pretax charge to R&D expenses in the fourth quarter of 2023. Despite these investments and charges, Merck maintained a strong cash flow from operations.
Merck 8-K Report, Financial Results (Oct 26, 2023)
Merck reported third-quarter 2023 results with total sales of $16.0 billion, up 7% year over year (9% excluding foreign exchange). Growth was led by oncology and vaccines: KEYTRUDA sales rose 17% to $6.3 billion and GARDASIL/GARDASIL 9 rose 13% to $2.6 billion. LAGEVRIO contributed $640 million (up 47%). GAAP EPS was $1.86, up 45%, while non-GAAP EPS was $2.13, up 15%. The improvement was partly offset by unfavorable foreign exchange and by the absence of 2022 charges tied to Moderna, Orna and Orion agreements and intangible asset impairments. The most important item for investors is the sharply lower full-year 2023 non-GAAP EPS guidance, now $1.33 to $1.38, down from $2.95 to $3.05. The cut reflects a $5.5 billion ($1.70 per share) pretax upfront charge for the Daiichi Sankyo ADC collaboration, along with acquisition-related charges and roughly 6 percentage points of foreign exchange headwind. Excluding these items, management says the business was approximately $0.15 per share stronger than previously expected. Sales guidance was raised to $59.7 to $60.2 billion from $58.6 to $59.6 billion, and the non-GAAP effective tax rate guidance rose to 39% to 40% from 30.5% to 31.5%, driven by business development charges. Pipeline progress was also significant. The FDA approved KEYTRUDA for resectable early-stage NSCLC, and priority reviews were granted for sotatercept (PDUFA date March 26, 2024), KEYTRUDA in cervical cancer, and WELIREG in RCC. Merck also started new Phase 3 programs in 2023, including the oral PCSK9 inhibitor MK-0616. Investors should watch the Keytruda growth trajectory, the impact of the Daiichi Sankyo deal on future R&D spending, and the upcoming regulatory decisions.
Merck Quarterly Report for Q2 Ended Jun 30, 2023
Merck & Co., Inc. reported net sales of $15.0 billion for the second quarter of 2023, a 3% increase year-over-year, driven by strong performance in its Oncology and Vaccines segments, particularly Keytruda and Gardasil 9. However, the company recorded a significant net loss of $5.97 billion ($2.35 loss per share) for the quarter, a stark contrast to the net income of $3.94 billion ($1.56 earnings per share) in the prior year period. This loss was largely attributable to a substantial charge related to the acquisition of Prometheus Biosciences, Inc., which impacted research and development expenses. Despite the quarterly loss, the company's financial position remains robust, with significant cash reserves and operational cash flow generation.
Merck 8-K Report, Financial Results (Aug 1, 2023)
Merck reported second-quarter 2023 results on August 1, 2023, with total sales of $15.0 billion, up 3% reported and 7% excluding foreign exchange (11% excluding LAGEVRIO, the COVID antiviral). The headline is a GAAP loss of $2.35 per share, versus EPS of $1.55 a year earlier. The loss is driven by a $10.2 billion (about $4.02 per share) one-time charge for the acquisition of Prometheus Biosciences, which is recorded in R&D and carries no tax benefit. Non-GAAP loss per share was $2.06, compared with non-GAAP EPS of $1.87 in the prior-year quarter. Underlying demand was strong: KEYTRUDA sales rose 19% to $6.3 billion, and GARDASIL/GARDASIL 9 rose 47% to $2.5 billion, with the core oncology and vaccine franchises carrying the growth. Investors should look past the reported loss to the operating trends. Gross margin improved to 73.2% GAAP and 76.6% non-GAAP, helped by lower low-margin LAGEVRIO sales and favorable product mix. LAGEVRIO fell 83% to $203 million, and this decline is the main drag on reported growth. Management raised and narrowed its full-year 2023 sales guidance to $58.6 billion to $59.6 billion, including about $1.0 billion of LAGEVRIO. It lowered the non-GAAP EPS outlook to $2.95 to $3.05, a range that now reflects the Prometheus charge and about $0.24 per share of underlying business strength. Foreign exchange is a meaningful headwind, costing about 2 points of sales growth and about 5 points of EPS. The quarter also advanced the pipeline. Merck completed the Prometheus acquisition, which adds MK-7240 (formerly PRA-023) to its immunology franchise. It also submitted a Biologics License Application for sotatercept in pulmonary arterial hypertension, reported positive Phase 3 data for the V116 pneumococcal vaccine, and presented KEYTRUDA data across earlier-stage cancers. Key risks include the post-COVID decline in LAGEVRIO, erosion of JANUVIA/JANUMET from generic competition, currency movements, and the R&D spending implied by the Prometheus deal.
Merck 8-K Report, Shareholder Vote Results (May 26, 2023)
Merck & Co., Inc. (MRK) filed an 8-K on May 25, 2023, detailing the results of its Annual Meeting of Shareholders held on May 23, 2023. The primary focus of the filing is the shareholder votes on various proposals, including the election of directors, executive compensation, and several shareholder-submitted proposals. All director nominees were overwhelmingly elected, and shareholders approved the appointment of the independent registered public accounting firm for 2023 with strong support. Investors will note that shareholders overwhelmingly supported an annual advisory vote on executive compensation and favored an "one year" frequency for future advisory votes on executive compensation. However, a significant number of shareholder proposals, concerning topics such as operations in China, access to COVID-19 products, political spending, patents, congruency reports, and board independence, were largely rejected by the majority of votes cast, indicating continued alignment between the board's recommendations and the majority shareholder sentiment on these specific issues.
Merck 8-K Report, Corporate Update (May 17, 2023)
Merck & Co., Inc. (MRK) filed an 8-K on May 17, 2023, to report the closing of a significant underwritten public offering of senior notes. The company successfully raised a total of $6.25 billion across six different tranches, with maturities ranging from 2028 to 2063 and coupon rates varying from 4.050% to 5.150%. This offering indicates Merck's proactive approach to managing its capital structure and potentially funding future growth initiatives or refinancing existing debt. Investors should note that this filing is primarily informational, detailing the debt issuance. While it does not directly disclose new operational or financial performance data, the ability to raise such a substantial amount of capital at these rates suggests continued investor confidence in Merck's financial stability and long-term prospects. The specific use of proceeds is not detailed in this filing, which is common for debt offerings of this nature.
Merck Quarterly Report for Q1 Ended Mar 31, 2023
Merck & Co., Inc. reported sales of $14.49 billion for the first quarter of 2023, a decrease of 9% year-over-year, or 5% excluding foreign exchange impacts. This decline was primarily driven by significantly lower sales of Lagevrio (COVID-19 antiviral), which generated $392 million compared to $3.2 billion in the prior year period. Other contributing factors to the sales decrease included lower sales in the diabetes franchise (Januvia/Janumet) and the pneumococcal vaccine (Pneumovax 23). Despite the revenue decline, the company's R&D expenses increased significantly by 66% to $4.3 billion, largely due to the $1.2 billion charge for the acquisition of Imago BioSciences and upfront payments for collaborations. The company also announced a significant agreement to acquire Prometheus Biosciences for approximately $10.8 billion, expected to close in the third quarter of 2023. This strategic move aims to bolster its pipeline in immune-mediated diseases. Net income attributable to Merck & Co., Inc. decreased to $2.82 billion, or $1.11 per share, from $4.31 billion, or $1.70 per share, in the first quarter of 2022. This decrease reflects the lower sales and increased R&D expenses, partially offset by a significant improvement in gross margin due to lower Lagevrio sales and lower amortization expenses. The company's strategic acquisitions and R&D investments signal a focus on future growth areas, though current financial results are impacted by the wind-down of certain pandemic-related products.
Merck 8-K Report, Financial Results (Apr 27, 2023)
Merck reported first-quarter 2023 results on April 27, 2023, with total sales of $14.5 billion, down 9% from $15.9 billion a year earlier. The decline was driven by a 88% drop in COVID-19 antiviral LAGEVRIO sales ($392 million vs. $3.2 billion). Excluding LAGEVRIO, sales grew 11%, and excluding LAGEVRIO and foreign exchange, growth was 15%. The core franchise remained strong: KEYTRUDA rose 20% to $5.8 billion and GARDASIL/GARDASIL 9 rose 35% to $2.0 billion. Non-GAAP EPS was $1.40 versus $2.14 a year earlier, and GAAP EPS was $1.11 versus $1.70. The year-over-year EPS declines were largely due to $0.52 per share of charges tied to the Imago BioSciences acquisition and the Kelun-Biotech collaboration, plus lower LAGEVRIO sales and unfavorable currency effects. GAAP results also carried a $573 million charge for Zetia antitrust settlements. Management raised and narrowed its full-year 2023 sales guidance to $57.7–$58.9 billion, including about $1.0 billion of LAGEVRIO sales, and raised non-GAAP EPS guidance to $6.88–$7.00. GAAP EPS guidance was lowered to $5.85–$5.97 because of the Zetia charge. The outlook excludes the pending Prometheus Biosciences acquisition, which is expected to close in Q3 2023 for $10.8 billion in equity value. Merck expects that deal to produce a one-time charge of roughly $10.3 billion, or about $4.00 per share, and an ongoing EPS drag of about $0.25 in the first 12 months after close. The quarter also brought pipeline news, including positive Phase 3 STELLAR data for sotatercept in pulmonary arterial hypertension, positive Phase 2b data for the oral PCSK9 inhibitor MK-0616, and an FDA accelerated approval of KEYTRUDA with Padcev for urothelial carcinoma. Investors should weigh the strong underlying growth in KEYTRUDA and vaccines against the near-term earnings impact of the Prometheus transaction and the fading LAGEVRIO contribution.
Merck Annual Report, Year Ended Dec 31, 2022
Merck & Co., Inc. reported robust performance in 2022, with total sales reaching $59.3 billion, a 22% increase year-over-year, driven significantly by its oncology franchise, particularly Keytruda, and strong sales from Lagevrio (a COVID-19 treatment). The company continues to focus on strategic business development, announcing several collaborations and acquisitions to bolster its pipeline in key therapeutic areas like oncology and infectious diseases. While sales growth was strong, investors should note the expected significant decline in Lagevrio sales for 2023, as the COVID-19 pandemic's impact wanes. Merck also highlighted its commitment to returning value to shareholders through dividends and share repurchases, alongside ongoing investments in research and development to drive future growth. Key risks and challenges identified include the ongoing pricing pressures in the healthcare industry, competition from generic products, and potential impacts from global economic conditions and regulatory changes, such as the Inflation Reduction Act. The company's patent portfolio remains crucial, with ongoing efforts to defend intellectual property rights against challenges.
Merck 8-K Report, Financial Results (Feb 2, 2023)
Merck reported fourth-quarter and full-year 2022 results on February 2, 2023, showing strong top-line momentum led by oncology and vaccines. Full-year 2022 worldwide sales rose 22% to $59.3 billion (12% growth excluding LAGEVRIO, and 15% excluding both LAGEVRIO and foreign exchange). KEYTRUDA grew 22% to $20.9 billion and GARDASIL/GARDASIL 9 grew 22% to $6.9 billion. Fourth-quarter sales were $13.8 billion, up 2% reported but up 8% excluding foreign exchange. Results are presented on a continuing operations basis, excluding Organon, which was spun off in 2021. Earnings were weaker than the top line suggests. Full-year GAAP EPS from continuing operations was $5.71, up 17%, while non-GAAP EPS was $7.48, up 39%. The fourth-quarter GAAP EPS of $1.18 fell 22% year over year, and non-GAAP EPS of $1.62 fell 10%. Fourth-quarter results were pressured by lower 2021 tax rates, unfavorable foreign exchange, losses on equity investments versus gains a year earlier, and intangible asset impairment charges of $780 million, largely related to nemtabrutinib. Full-year 2022 EPS was also reduced by $0.22 from collaboration and licensing charges with Moderna, Orna and Orion. Non-GAAP results in 2022 no longer exclude these collaboration charges, and 2021 has been recast to match. The 2023 outlook calls for sales of $57.2 billion to $58.7 billion, which includes about $1.0 billion of LAGEVRIO sales, a sharp decline from 2022. GAAP EPS is guided to $5.86 to $6.01 and non-GAAP EPS to $6.80 to $6.95. The guidance absorbs about $0.53 per share of charges from the Imago acquisition (closed January 2023) and the Kelun-Biotech license, which together add roughly $1.4 billion of R&D expense. The outlook does not assume further significant business development deals.
Merck Quarterly Report for Q3 Ended Sep 30, 2022
Merck & Co., Inc. (MRK) reported strong third-quarter and year-to-date results for 2022, showcasing significant sales growth driven by Keytruda and Lagevrio. Total sales increased by 14% in the third quarter to $14.96 billion and by 29% for the first nine months to $45.45 billion. This growth was primarily fueled by a robust performance in the oncology franchise, led by Keytruda, and substantial contributions from Lagevrio in the virology segment. The company also saw positive momentum in its vaccines and hospital acute care products. Despite these strong top-line results, the company is navigating ongoing pricing pressures and global economic uncertainties, including the impact of the war in Ukraine, which, however, remained immaterial to the financial statements for the period. Merck's strategic investments in research and development, particularly in oncology and other key therapeutic areas, continue to drive its pipeline. The company is also managing its cost structure through restructuring initiatives, aiming for long-term efficiency. Overall, Merck demonstrates financial resilience and strategic focus amidst a dynamic market environment.
Merck 8-K Report, Financial Results (Oct 27, 2022)
Merck's Q3 2022 results showed strong top-line momentum: worldwide sales rose 14% to $15.0 billion (18% excluding foreign exchange), led by KEYTRUDA (+20% to $5.4 billion) and GARDASIL/GARDASIL 9 (+15% to $2.3 billion), with LAGEVRIO contributing $436 million. GAAP EPS from continuing operations was $1.28, down 29% year over year, while non-GAAP EPS rose 4% to $1.85. The GAAP decline was driven largely by acquisition- and divestiture-related costs (including collaboration and licensing charges tied to Moderna, Orna and Orion), an $887 million intangible asset impairment related to the ArQule acquisition, and $350 million of net losses on equity securities. Management raised its full-year 2022 sales outlook to $58.5-59.0 billion (about 20-21% growth) and narrowed non-GAAP EPS guidance to $7.32-7.37, but lowered GAAP EPS guidance to $5.68-5.73. The non-GAAP raise was partly offset by a $250 million option payment to Moderna and roughly 4% negative FX impact. Leadership change was also disclosed. Kenneth C. Frazier, Executive Chairman, will retire from the Board effective November 30, 2022, and CEO Robert M. Davis was elected by the Board to succeed him as Chairman effective December 1, 2022. For investors, this is a governance transition rather than an operational change, since Davis already leads the company and Frazier had served as executive chairman since July 2021. Key near-term watch items include the GAAP-to-non-GAAP gap, which widened materially as Merck stopped excluding upfront and milestone payments from non-GAAP results in 2022, pipeline catalysts such as sotatercept (STELLAR Phase 3 positive), the Lynparza PROpel FDA decision expected in Q4 2022, and the continued pace of LAGEVRIO sales as COVID-19 antiviral demand evolves.
Merck Quarterly Report for Q2 Ended Jun 30, 2022
Merck & Co., Inc. (MRK) reported strong financial results for the quarter ended June 30, 2022. Net sales increased significantly year-over-year, driven by robust performance across key franchises, particularly in Oncology (Keytruda) and Vaccines (Gardasil/Gardasil 9). The company also saw substantial contributions from its antiviral medication Lagevrio. Despite increased costs, especially related to the collaboration with Ridgeback for Lagevrio, Merck maintained healthy profitability. The company's strategic investments in research and development and business development initiatives, including collaborations in July 2022 for ODM-208 and MK-1200, position it for future growth. Merck also reiterated its full-year 2022 sales guidance for Lagevrio, expecting between $5.0 billion and $5.5 billion.
Merck 8-K Report, Financial Results (Jul 28, 2022)
Merck reported second-quarter 2022 results on July 28, 2022 that were strong on the top line and raised the low end of its sales outlook. Worldwide sales rose 28% to $14.6 billion (31% excluding foreign exchange), with LAGEVRIO contributing $1.2 billion. Excluding LAGEVRIO, growth was 18%, and excluding LAGEVRIO and FX it was 20%. KEYTRUDA grew 26% to $5.3 billion and GARDASIL/GARDASIL 9 grew 36% to $1.7 billion. Growth was broad across oncology, vaccines and hospital acute care, with COVID-19 recovery providing a tailwind because the prior-year quarter was depressed. Profitability was more mixed. GAAP EPS was $1.55 versus $0.48 a year earlier, but that comparison is distorted by the prior-year $1.7 billion Pandion acquisition charge. Non-GAAP EPS was $1.87. GAAP results were weighed down by net unrealized losses on equity investments, higher pension settlement costs, higher acquisition-related costs and a lower non-GAAP gross margin (74.7%, down from 76.5%) caused by LAGEVRIO profit sharing with Ridgeback. Management raised and narrowed full-year sales guidance to $57.5-58.5 billion (18-20% growth), a more than 1% incremental FX headwind relative to prior guidance. It narrowed non-GAAP EPS guidance to $7.25-7.35, absorbing a $290 million upfront payment to Orion and higher U.S. pension settlement expense against roughly $0.25 of operational strength. GAAP EPS guidance is $5.89-5.99. For investors, the key takeaways are the durability of KEYTRUDA and vaccine demand, the sizable but temporary contribution of LAGEVRIO, and a guidance range that absorbs FX and business development costs. The filing also contains forward-looking statements and risk factors, including competition, patent exposure, pricing pressure and regulatory outcomes.